market research report : oncology pharmaceuticals market in india 2014 - sample

1

Oncology Pharmaceuticals Market-India

August 2011

Oncology Pharmaceuticals Market in India

September 2014

http://www.netscribes.com/


2 ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT

Drivers: Increasing number of cancer cases Changes in the treatment scenario Development of alternative cancer therapies Increase in cancer insurances Increase in FDI

Drug regulation and patents

Oncology pharmaceuticals market in India is valued at INR x bn in 20— Fourth largest in volume, eighth largest in value in the world market Market is expected to grow at a CAGR of y% from20-----

Challenges: Increased competition Drug patents problem Drug Portfolio management

Government Initiatives

Reforms in tax structure Reduction in drug prices Public –Private Partnership (PPP) programmes Drug control programmes

Phases of clinical trial Approval and licensing of drugs Patents

Competition

Highly fragmented market with large number of players Major public players in the market include Company A,Company B, Company C, Company D,

Company E, Company F, Company G, Company H, Company I, Company J Major private companies include Company K, Company L, Company M

Drivers and Challenges

Market

Executive Summary


3

•Macro-Economic Indicators

•Introduction

•Market Overview

•Export-Import

•Market Value Chain

•Drivers & Challenges

•Government Initiatives

•Regulations

•Competitive Landscape

•Recent Developments

•Strategic Recommendations

•Appendix

ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT


4

Economic Indicators (1/3)

11

12

13

14

15

INR tn

Q4

c4

b4

a4

Q3

c3 b3

a3

Q2

d2 c2

b2

a2

Q1

d1 c1

b1

a1

2013-14 2012-13 2011-12 2010-11

GDP at Factor Cost: Quarterly

Inflation Rate: Monthly

-2

-1

0

1

2

q

Aug 2013 - Sep 2013

r

Sep 2013 - Oct 2013 Jul 2013 - Aug 2013

p

Nov 2013 - Dec 2013

t

Oct 2013 - Nov 2013

%

s



5

Indian oncology pharma market has grown enormously over the last few years

•Fourth largest in volume, eighth largest in value in the world market

•Expected to reach INR y bn in 20--

•Cancer is the second largest cause of death in the country

•According to the National Cancer Registry Program (NCRP) there are z mn cancer patients at any point of time

•There occurs X cancer related deaths each year

•Oral and lung cancer are the most common in males, while in females, cervical, followed by breast and ovarian cancer are the most common

•Availibilty of xx oncologists per yy people in India

Indian market-overview Market size

Source:

Increase in Cancer Cases

0

200

400

600

800

1,000

1,200

In ‘000

20--

x

20--e

n%

y

0

10

20

30

40

50

INR unit

20-- 20--e 20--e 20--e 20--e 20--e 20--

m% g

f e

d c b a



6

A huge volume of cancer drugs is exported to many countries…

• Highly fragmented market with many domestic

manufacturers lead to huge volume of exports

• India currently exports to more than 115 countries

• Between 20-- - 20-- and 20-- - 20-- the value of export

of oncology pharmaceuticals rose by m%

• Country A accounted for the highest exports in 20-- -

20-- while Country B ranked highest in 20-- - 20--

Exports of Oncological Pharmaceuticals Total Exports

Exports – Region wise (20-- - 20--) Exports – Region wise (20-- - 20--)

0

1,000

2,000

3,000

4,000

INR units

20– to 20--

e2

20–to 20--

e1

P%

e5

20– to 20--

e4

20– to 20--

e3

20– to 20--

Note: All figures are for financial year Source: Ministry of Commerce: Export-Import Data Bank

D1% C1%

E1%

G1%

B1%

A1%

E2%

G2%

D2%

A2%

B2%

F2%

Country F

Country D

Country E

Country G

Country C

Country B

Country A



7

Drivers & Challenges - Summary

Drivers

Increasing number of cancer cases

Changes in the treatment scenario

Development of alternative cancer therapies

Increase in cancer insurances

Increase in the amount of FDI

Challenges

Increased competition

Drug patent problems

Drug portfolio management

Lack of affordability



8

Government initiatives

Reforms in tax structure

Public-Private-partnership

(PPP) projects

Cancer control programmes

Reduction in drug prices

Government Initiative



9

SAMPLE Porter’s Five Forces Analysis

Competitive Rivalry • Texttext texttext texttext texttext

texttext texttext texttext • Texttext texttext texttext texttext

texttext texttext texttext

Bargaining Power of Buyers • Texttext texttext texttext

texttext texttext texttext texttext

• Texttext texttext texttext texttext texttext texttext texttext

Threat of New Entrants • Texttext texttext texttext texttext



Impact Low to

Medium

Impact Medium to

High

Impact High

Bargaining Power of Suppliers • Texttext texttext texttext texttext




Impact Low to

Medium

Threat of Substitutes • Texttext texttext texttext texttext



Impact Low



10

SAMPLE Competitive Benchmarking (1/5)

Public Trading Comparables (FY 2013) – Top 3 Companies

Company A Company B Company C

Market Capitalization (INR mn) Value Value

Value

Share Price (INR) Value Value Value

EV/EBITDA (INR mn) Value Value Value

EV/Revenue (INR mn) Value Value Value

PE Ratio Value Value Value

Note: Top 3 Public companies based on the Market Capitalization, Share Price and PE ratio is as of 18/05/2014



11

SAMPLE Key Ratios of Top 3 Companies – Operational Basis (FY 20--) (1/3)

Competitive Benchmarking (1/4)

-30

-20

-10

0

10

%

Player C

q3

Player B

q2 p2

Player A

q1 p1

Net Margin Operating Margin

• X

• X



12

Public: Domestic Company – Company A (1/3)

Key People

Products and Services

Company Information Offices and Centres – India

Corporate Address X Road

Bangalore

Tel No. +91 xx xxxxx xxxxx

Fax No. +91 xx xxxxx xxxxx

Website www.ppp.com

Year of

Incorporation 19--

Ticker Symbol xxxxxx

Stock Exchange NNN

Name Designation

Person M Founder

Person N CFO

Person O Head

Person Q President

City A Products and Services Head Office

Source:

Category Products/Services

Pharmaceutical CVD, oncology, CNS, respiratory, dermatology, orthopedics, nutritional, urology, anti-infectives

Molecule Development

Infectious diseases, metabolic diseases, inflammatory/respiratory diseases, and oncology



http://www.ppp.com/

13

Source:

Key Ratios

Financial Summary

Public: Domestic Company – Company B (2/3)

• The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20--

• The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20--

• The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20--

• The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20--

Financial Summary

Profit / Loss

Revenue Profit

INR mn

p

n

0

-m

Revenue INR mn

0

20--

t p

20--

s

o

20--

r

n

20--

q

m

10,000

5,000

Indicators Present Value

Market Capitalization (INR) X units

Total Enterprise Value (INR) Y units

EPS (INR) Z units

PE Ratio (Absolute) A

Particulars y-o-y change 20-- 20-- 20-- 20--

Profitability Ratios Operating Margin

Net Margin

Profit Before Tax Margin

Return on Equity

Return on Capital Employed

Return on Working Capital

Return on Assets

Return on Fixed Assets

Cost Ratios Operating costs (% of Sales)

Administration costs (% of Sales)

Interest costs (% of Sales)

Liquidity Ratios Current Ratio

Cash Ratio

Leverage Ratios Debt to Equity Ratio

Debt to Capital Ratio

Interest Coverage Ratio

Efficiency Ratios Fixed Asset Turnover

Asset Turnover

Current Asset Turnover

Working Capital Turnover

Capital Employed Turnover

Improved Decline

Financial Snapshot



14

Public: Domestic Company – Company C (3/3)

y

x

20--

z y

x

20--

z y

x

20--

z y

x

20--

z

o n m

Key Business Segments

20--

z

y

x

20--

z

y

x

20--

z

y

x

20--

z

y

x

x y z

Key Geographic Segments

Source:

Key Recent Developments

Description News

Overview • Company A is an integrated research based company that produces a wide range of generic medicines

• Serves customers in over 100 countries with manufacturing facilities in several countries

Oncology Pharmaceuticals • Products include include Product 1 and Product 2

Key Initiatives • Is making consistent effort for continual improvement in rural areas with respect to accessibility of

medicines



15

Thank you for the attention

About Netscribes, Inc. Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.

Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Series. For any queries or customized research requirements, contact us at:

Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.

Phone: +91 22 4098 7600 E-Mail: [email protected]




mailto:[email protected]

market research report : oncology pharmaceuticals market in india 2014 - sample

Business

company e

company f

company d

company h

company g

company mdrivers

lung cancer

cancer insurancesincrease